DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)

Information source: NeurogesX
ClinicalTrials.gov processed this data on August 20, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Herpes Zoster; Neuralgia; Pain; HIV Infections; Peripheral Nervous System Diseases

Intervention: Capsaicin Dermal Patch (Drug)

Phase: Phase 2

Status: Completed

Sponsored by: NeurogesX

Official(s) and/or principal investigator(s):
Jeffrey Tobias, MD, Study Director, Affiliation: NeurogesX

Summary

The purpose of the study is to evaluate the safety and efficacy of NGX-4010 administered at intervals of no less than 12 weeks over 1 year, based on the presence or return of pain, for the treatment of painful HIV-AN and PHN. Participation is limited to former study subjects from previous trials of NGX-4010 at selected sites.

Clinical Details

Official title: A Multicenter, Open-Label, Phase 2 Study of NGX-4010 for the Treatment of Neuropathic Pain in Patients With Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)

Study design: Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Mean percent change from baseline in "average pain for the past 24 hours" NPRS score (i.e., average of scores during Weeks 12 and 48, compared to baseline).

Secondary outcome:

Proportion of subjects who score 2 or 3 ("Much Improved" or "Very Much Improved") on Patient Impression of Change at Weeks 12, 24, 36 and 48.

Proportion of subjects with significant changes in concomitant pain medication usage during the 2nd through 12th week following study patch application.

Detailed description: Study C118 is a multicenter, open-label, single-arm study for subjects who successfully completed a previous NGX-4010 study and have not received open-label or blinded NGX-4010 study patches within the 12 weeks prior to study entry. One hundred eligible subjects will receive an initial open-label NGX-4010 study patch application and up to three additional open-label NGX-4010 applications at intervals of no less than 12 weeks, based on the presence or return of pain. Eligible subjects will have moderate to severe neuropathic pain secondary to HIV-AN or PHN, with average pain levels deemed appropriate for further treatment with NGX-4010 as judged by the Investigator.

Eligibility

Minimum age: N/A. Maximum age: N/A. Gender(s): Both.

Criteria:

Summary eligibility criteria:

- Subjects must be in good health and have successfully completed a past trial of

NGX-4010 with no past occurrence of adverse events that would contraindicate further treatment.

- The time between the last study patch on the previous study and the first study patch

on this study must be at least 12 weeks.

- Topical pain medications are exclusionary and require washout prior to study patch

application for this study.

- Chronic, nontopical pain medications are allowed but must be stable (not as needed)

for a defined period prior to first study patch application.

- Other specific inclusion and exclusion criteria must be met prior to enrollment on

the study.

Locations and Contacts

Additional Information

Starting date: August 2005
Last updated: March 4, 2008

Page last updated: August 20, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017